We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
+21.2%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$132M
AUM Growth
+$12.1M
Cap. Flow
-$15
Cap. Flow %
-0%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$15

Sector Composition

Rank Sector Weight
1 Healthcare 95.63%
2 Communication Services 4.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$69.6M 52.94%
3,766,666
-1
-0% -$15
TVRD
2
Tvardi Therapeutics
TVRD
$23.5M
$51.4M 39.1%
88,696
– –
LVO icon
3
LiveOne
LVO
$66M
$5.75M 4.37%
372,414
– –
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
$4.56M 3.47%
31,858
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$254M
$146K 0.11%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Rho Capital Partners held 5 positions worth $132M, up 10% from $119M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q4 2019: portfolio turnover was 0%. Rho Capital Partners opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Communication Services.

  • Rho Capital Partners's biggest Q4 2019 reduction was NGM Biopharmaceuticals, Inc. Common Stock, cutting an estimated $15.
  • Rho Capital Partners's ten largest holdings make up 100% of its $132M portfolio in Q4 2019.
  • Rho Capital Partners opened 0 new positions and closed 0 in Q4 2019.
  • Rho Capital Partners's portfolio value rose 10% quarter-over-quarter to $132M.

Based on Rho Capital Partners's 13F filing for Q4 2019, filed 13 Feb 2020.